What are the management recommendations for a 59-year-old woman with essential hypertension who is taking hydrochlorothiazide 25 mg daily and has a recent blood pressure of 129/86 mm Hg?

Management of Blood Pressure 129/86 mmHg on Hydrochlorothiazide 25 mg Daily

Continue current hydrochlorothiazide 25 mg daily and add a second antihypertensive agent—specifically a RAS blocker (ACE inhibitor or ARB)—to achieve the target systolic blood pressure of 120-129 mmHg. 1

Current Blood Pressure Status

Your patient's blood pressure of 129/86 mmHg places her in the elevated/stage 1 hypertension range despite monotherapy. 1 While this represents partial control, the 2024 ESC guidelines explicitly recommend targeting systolic BP to 120-129 mmHg in most adults to reduce cardiovascular risk, provided treatment is well tolerated. 1 The 2025 AHA/ACC guidelines similarly emphasize achieving optimal BP targets. 2

Recommended Treatment Intensification

Add Combination Therapy

• Initiate a two-drug combination by adding either an ACE inhibitor or ARB to the existing hydrochlorothiazide 25 mg. 1
• The 2024 ESC guidelines state that combination BP-lowering treatment is recommended for most patients with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy, and your patient's BP of 129/86 mmHg warrants intensification to reach the 120-129 mmHg target. 1
• Preferred combinations are a RAS blocker (ACE inhibitor or ARB) with a thiazide diuretic, which provides complementary mechanisms of action. 1

Specific Drug Options

• Consider valsartan/hydrochlorothiazide fixed-dose combination (80 mg/12.5 mg or 80 mg/25 mg), which has demonstrated significant additional BP reduction compared to thiazide dose escalation alone. 3, 4
• Alternative options include perindopril/hydrochlorothiazide or irbesartan/hydrochlorothiazide combinations, all of which have proven efficacy and tolerability. 5, 6
• Fixed-dose single-pill combinations are recommended over separate pills to improve adherence. 1

Why Not Simply Increase Hydrochlorothiazide Dose?

• Hydrochlorothiazide demonstrates dose-related BP lowering, with 25 mg reducing BP by 8/3 mmHg and 50 mg by 11/5 mmHg compared to placebo. 7
• However, doses greater than 50 mg daily are not recommended per FDA labeling. 8
• More importantly, adding a RAS blocker provides superior BP reduction (11.3 mmHg systolic) compared to doubling the thiazide dose (5.7 mmHg systolic). 3
• Higher thiazide doses increase metabolic adverse effects, particularly hypokalemia, hyperuricemia, and glucose intolerance, without proportional BP benefit. 7, 9

Metabolic Monitoring Considerations

• Monitor serum potassium as hydrochlorothiazide 25 mg can cause significant potassium depletion. 10, 7
• Check fasting glucose and lipids since thiazides can impair glucose tolerance and increase total cholesterol and triglycerides in a dose-dependent manner. 7, 9
• The 25 mg dose already carries metabolic risk; increasing it further would worsen these effects. 9

Blood Pressure Target Rationale

• The 2024 ESC guidelines explicitly recommend targeting systolic BP to 120-129 mmHg in most adults to reduce cardiovascular disease risk. 1
• At 59 years old without mention of frailty or orthostatic hypotension, this patient does not fall into the exceptions category (age ≥85 years, symptomatic orthostatic hypotension, moderate-to-severe frailty). 1
• Thiazides produce greater pulse pressure reduction (4-6 mmHg) compared to other antihypertensive classes, which is particularly beneficial for cardiovascular outcomes. 7

Implementation Strategy

• Add an ACE inhibitor or ARB to the current hydrochlorothiazide 25 mg regimen rather than switching medications entirely, as thiazides remain first-line agents with proven cardiovascular benefit. 1
• Use fixed-dose combination therapy when available to enhance adherence. 1
• Reassess BP in 4-8 weeks after initiating combination therapy to determine if target is achieved. 1
• If BP remains uncontrolled on two-drug combination, escalate to three-drug therapy (RAS blocker + CCB + thiazide). 1

Common Pitfalls to Avoid

• Do not combine two RAS blockers (ACE inhibitor with ARB), as this increases cardiovascular and renal risk without additional benefit. 1
• Do not use beta-blockers as add-on therapy unless there are compelling indications such as coronary artery disease, heart failure, or arrhythmia requiring rate control. 1
• Do not discontinue the thiazide when adding a second agent, as thiazides have the most robust evidence for reducing cardiovascular events and mortality. 1